Individual values for two patients for erect and supine blood pressure, terminal latency (TL) and motor nerve conduction velocity (MCV) of ulnar and peroneal nerves, and Valsalva ratio (VR)5 at presentation and after withdrawal of perhexiline coronary angiography was carried out. He subsequently died after a further attempt at surgical revascularisation. Case 2-A 60-year-old man presented in 1968 with symptoms of angina pectoris that progressed despite treatment with propranolol. In 1973 after coronary angiography he underwent triple aortocoronary saphenous vein grafts, but there was no real improvement in his symptoms, and he remained severely incapacitated. In July 1975 he started treatment with perhexiline (200 mg increased to 400 mg/day) with some relief of angina. He returned in June 1976 with a two-month history of weakness and paraesthesiae in both legs and numbness in both feet, and distressing symptoms of postural dizziness. Examination showed sensory blunting below the knee with weakness of all muscle groups in the legs. Systolic blood pressure was 110 mm Hg lying and 90 mm Hg erect. MCV in both arms and legs was delayed and VR reduced (table) . Four weeks after withdrawal of perhexiline, his postural hypotension had resolved and VR had become normal. The symptoms of neuropathy had also improved, although three months after discontinuing the drug he still had paraesthesiae in both feet with reduced MCV in the peroneal nerve. He remained incapacitated by angina.
Case 
Comment
Three patients developed clinical features of peripheral and autonomic neuropathy on perhexiline maleate. In two cases the features developed after prolonged treatment, and the diagnosis was confirmed by abnormal results of motor nerve conduction velocity and autonomic function tests. In the third case deterioration of known autonomic neuropathy secondary to diabetes mellitus occurred after a short period on the drug. In all three cases there was symptomatic improvement within a few weeks of discontinuing treatment, suggesting a direct association with the drug. Improvement in motor nerve conduction velocity and autonomic function test results lagged behind the symptomatic improvement in these patients, but in patient 2 results of these tests were almost normal three months after discontinuing the drug.
Lhermitte et alP have postulated that peripheral neuropathy may represent individual susceptibility perhaps secondary to some latent inborn metabolic disorder. Further information on the incidence of test results showing impairment of motor nerve conduction velocity and autonomic function in patients taking perhexiline without symptoms or signs of neuropathy is needed before accepting this theory. The development of symptomatic autonomic neuropathy, particularly postural hypotension, is obviously an undesirable side effect in any patient with angina pectoris.
Burns-Cox, C J, et al, British Medical3Journal, 1971, 4, 586. 2 Bousser, M G, et al, Nouvelle Presse Medicale, 1976, 5, 652. 3Lhermitte, F, et al, British Medical3Journal, 1976 , 1, 1256 Although retinal vein distension, fundal haemorrhages, and blurring of the optic disc margins are well-recognised features of chronic granulocytic leukaemia (CGL), true papilloedema is relatively rare.' We report a case where bilateral papilloedema was present at diagnosis and improved after repeated leukapheresis on a continuous flow cell separator.
Case history
A 33-year-old woman was admitted to hospital with a 12-month history of anorexia, weight loss, and fatigue. She admitted to recent deterioration in vision. She was pale and thin with splenomegaly to below the umbilicus. Both optic fundi showed venous distension, haemorrhages, and papilloedema consistent with leukaemic retinitis. The findings of full neurological examination were otherwise normal. Peripheral blood findings were as follows:
Hb 7-4 g/dl; platelets 470X 109/l; total WBC 260X 109/1 (neutrophils 44O,, metamyelocytes 900, myelocytes 18"o, promyelocytes 180,°, eosinophils 2 "0O, basophils 1 0 ,, lymphocytes 2 0),, blast cells 6°0 , nucleated RBCs 4/100 WBC).
Leuc6cyte alkaline phosphatase score 5 (normal 20-120). Bone marrow examination yielded initially a dry tap, but a later aspirate showed gross myeloid hyperplasia, and an increase in eosinophils and megakaryocytes, consistent with a diagnosis of CGL. The Philadelphia chromosome was present. Trephine bone marrow biopsy showed no features of myelofibrosis. Immunoglobulin concentrations were normal and no paraprotein band was detected. Whole blood viscosity, measured at 37 C in an Ostwald viscometer,2 was approximately twice normal (ratio patient's blood/water -7 7; ratio control blood matched for haematocrit value/water = 4.2). An EMI brain scan showed no abnormality-in particular, no dilatation of the ventricular system to suggest raised intracranial pressure. Fluorescein angiography confirmed swelling of the optic nerve head.
CGL was diagnosed and, because of the very high WBC count, primary treatment was by leukapheresis, initially daily and later twice weekly, on a continuous flow cell separator. A total of 3 22X 1012 leucocytes, of which 1 86 x 1012 were immature myeloid cells, were removed over a period of 26 days. By day 21, after eight such treatments, there was considerable improvement in the eye signs, with disappearance of most of the haemorrhages and Appearances of fundus after eight leukaphereses showing resolving papilloedema. reduction in venous calibre. Disc swelling improved although the margins remained blurred (see figure) . Whole blood viscosity fell immediately to within normal limits (patient ratio 3 56; control ratio 4 0), although the WBC count remained fluctuant between 50 and 190X 10/1. The spleen regressed in size by 4-5 cm and at the same time there was subjective restoration of normal vision. Treatment was then continued with busulphan. The patient remained well with no new retinal or neurological signs five months later. Total WBC, platelets, and Hb levels were within normal limits, although some early myeloid cells were still seen in the peripheral blood. The 
Discussion
Inhibitors active specifically against factor V are rare: only 12 other reports could be found.25 Some had had streptomycin or blood transfusion at a variable interval before the factor V inhibitor made itself apparent clinically.2 3 5 Nevertheless, our patient had not received streptomycin and was given a blood transfusion only after the onset of her bleeding disorder.
The poor generation of fibrin in the fibrinogen assay clot-weight system and the slow clotting of the blood transfusion sample raised the possibility of defibrination syndrome. Nevertheless, the normal fibrinogen level, thrombin time, and platelet count were all against this. The results of other investigations confirmed the presence of a factor V inhibitor. The reduced factor X concentration may have been an artefact caused by the presence of the factor V inhibitor interfering with the one-stage assay system.
